Compare Axogen Inc (AXGN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Sana Biotechnology Inc — how do they compare? Axogen Inc trades at $48.91 (market cap $2.67B), while Sana Biotechnology Inc trades at $3.72 (market cap $1.13B). The key difference: Axogen Inc is far larger — about 2.4× Sana Biotechnology Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | SANA | |
|---|---|---|
Market Cap | $2.67B | $1.13B |
Sector | Technology | Health |
52-Week High | $49.67 | $5.92 |
52-Week Low | $14.76 | $2.68 |
Enterprise Value | $2.58B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
